Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma

Benjamin J Green, Surasa Wiriyachaiporn, Christopher Grainge, Geraint B Rogers, Valia Kehagia, Laurie Lau, Mary P Carroll, Kenneth D Bruce, Peter H Howarth, Benjamin J Green, Surasa Wiriyachaiporn, Christopher Grainge, Geraint B Rogers, Valia Kehagia, Laurie Lau, Mary P Carroll, Kenneth D Bruce, Peter H Howarth

Abstract

Background: Molecular microbiological analysis of airway samples in asthma has demonstrated an altered microbiome in comparison to healthy controls. Such changes may have relevance to treatment-resistant severe asthma, particularly those with neutrophilic airway inflammation, as bacteria might be anticipated to activate the innate immune response, a process that is poorly steroid responsive. An understanding of the relationship between airway bacterial presence and dominance in severe asthma may help direct alternative treatment approaches.

Objective: We aimed to use a culture independent analysis strategy to describe the presence, dominance and abundance of bacterial taxa in induced sputum from treatment resistant severe asthmatics and correlate findings with clinical characteristics and airway inflammatory markers.

Methods: Induced sputum was obtained from 28 stable treatment-resistant severe asthmatics. The samples were divided for supernatant IL-8 measurement, cytospin preparation for differential cell count and Terminal Restriction Fragment Length Polymorphism (T-RFLP) profiling for bacterial community analysis.

Results: In 17/28 patients, the dominant species within the airway bacterial community was Moraxella catarrhalis or a member of the Haemophilus or Streptococcus genera. Colonisation with these species was associated with longer asthma disease duration (mean (SD) 31.8 years (16.7) vs 15.6 years (8.0), p = 0.008), worse post-bronchodilator percent predicted FEV1 (68.0% (24.0) vs 85.5% (19.7), p = 0.025) and higher sputum neutrophil differential cell counts (median (IQR) 80% (67-83) vs 43% (29-67), p = 0.001). Total abundance of these organisms significantly and positively correlated with sputum IL-8 concentration and neutrophil count.

Conclusions: Airway colonisation with potentially pathogenic micro-organisms in asthma is associated with more severe airways obstruction and neutrophilic airway inflammation. This altered colonisation may have a role in the development of an asthma phenotype that responds less well to current asthma therapies.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Severe asthma disease duration and…
Figure 1. Severe asthma disease duration and inflammation related to abundance of Haemophilus., Streptococcus, and Moraxella sp.
The relationship in treatment-resistant severe asthma between total abundance of Haemophilus sp., Streptococcus sp., and Moraxella catarrhalis in induced sputum samples and [A] neutrophil differential cell count (%), [B] asthma duration (years), [C] interleukin (IL)-8 concentration in induced sputum and [D] the relationship between M. catarrhalis abundance and induced sputum IL-8 concentration.
Figure 2. Interleukin-8 sputum supernatant concentrations in…
Figure 2. Interleukin-8 sputum supernatant concentrations in severe asthma related to sputum neutrophil count and lung function.
The relationship in treatment-resistant severe asthma between IL-8 concentrations in induced sputum and (A) neutrophil differential cell counts and (B) Post bronchodilator percent predicted FEV1.

References

    1. Huang YJ, Nelson CE, Brodie EL, Desantis TZ, Baek MS, et al. (2011) Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol 127: 372–381.e1–3 10.1016/j.jaci.2010.10.048
    1. Marri PR, Stern DA, Wright AL, Billheimer D, Martinez FD (2013) Asthma-associated differences in microbial composition of induced sputum. J Allergy Clin Immunol 131: 346–52.e1–3 10.1016/j.jaci.2012.11.013
    1. Goleva E, Jackson LP, Harris JK, Robertson CE, Sutherland ER, et al. (2013) The effects of airway microbiome on corticosteroid responsiveness in asthma. Am J Respir Crit Care Med 188: 1193–1201 10.1164/rccm.201304-0775OC
    1. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, et al. (2010) Disordered microbial communities in asthmatic airways. PLoS ONE 5: e8578 10.1371/journal.pone.0008578
    1. Szefler SJ, Zeiger RS, Haselkorn T, Mink DR, Kamath TV, et al. (2011) Economic burden of impairment in children with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 107: 110–119.e111 10.1016/j.anai.2011.04.008
    1. Breekveldt-Postma NS, Erkens JA, Aalbers R, van de Ven MJT, Lammers J-WJ, et al. (2008) Extent of uncontrolled disease and associated medical costs in severe asthma—a PHARMO study. Curr Med Res Opin 24: 975–983 10.1185/030079908X280518
    1. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, et al. (1999) Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 160: 1532–1539.
    1. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ (1999) Non-eosinophilic corticosteroid unresponsive asthma. Lancet 353: 2213–2214 10.1016/S0140-6736(99)01813-9
    1. Bacci E, Cianchetti S, Bartoli M, Dente FL, Di Franco A, et al. (2006) Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 129: 565–572 10.1378/chest.129.3.565
    1. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, et al. (2002) Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57: 875–879.
    1. Simpson JL, Grissell TV, Douwes J, Scott RJ, Boyle MJ, et al. (2007) Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 62: 211–218 10.1136/thx.2006.061358
    1. Gibson PG, Simpson JL, Saltos N (2001) Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 119: 1329–1336.
    1. Yang IA, Fong KM, Holgate ST, Holloway JW (2006) The role of Toll-like receptors and related receptors of the innate immune system in asthma. Curr Opin Allergy Clin Immunol 6: 23–28 10.1097/
    1. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, et al. (2005) Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60: 1012–1018 10.1136/thx.2005.045260
    1. Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, et al. (2012) Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax 67: 867–873 10.1136/thoraxjnl-2011-200932
    1. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, et al. (2004) characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 42: 5176–5183 10.1128/JCM.42.11.5176-5183.2004
    1. Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, et al. (2003) Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 41: 3548–3558.
    1. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. (2000) Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Vol. 162 pp. 2341–2351.
    1. British Thoracic Society Scottish Intercollegiate Guidelines Network (2008) British Guideline on the Management of Asthma. Thorax 63 Suppl 4: iv1–iv121 10.1136/thx.2008.097741
    1. Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanovic R, et al. (2002) Sputum induction. The European respiratory journal Supplement 37: 3s–8s.
    1. Rogers GB, Zain NMM, Bruce KD, Burr LD, Chen AC, et al. (2014) A Novel Microbiota Stratification System Predicts Future Exacerbations in Bronchiectasis. Ann Am Thorac Soc. doi:10.1513/AnnalsATS.201310-335OC.
    1. Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, et al. (2007) Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 357: 1487–1495 10.1056/NEJMoa052632
    1. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS (2006) Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173: 991–998 10.1164/rccm.200509-1525OC
    1. Wilkinson TMA, Patel IS, Wilks M, Donaldson GC, Wedzicha JA (2003) Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167: 1090–1095 10.1164/rccm.200210-1179OC
    1. Banerjee D, Khair OA, Honeybourne D (2004) Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 23: 685–691.
    1. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, et al. (2002) Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57: 759–764.
    1. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, et al. (2013) Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 68: 731–737 10.1136/thoraxjnl-2012-203105
    1. Rogers GB, Skelton S, Serisier DJ, van der Gast CJ, Bruce KD (2010) Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. J Clin Microbiol 48: 78–86 10.1128/JCM.01324-09
    1. Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, et al. (1996) Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 154: 308–317.
    1. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, et al. (2006) Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol 44: 2601–2604 10.1128/JCM.02282-05
    1. Cabrera-Rubio R, Garcia-Núñez M, Setó L, Antó JM, Moya A, et al. (2012) Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. J Clin Microbiol 50: 3562–3568 10.1128/JCM.00767-12
    1. Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG (2005) Macrolides for chronic asthma. Cochrane Database Syst Rev: CD002997. doi:10.1002/14651858.CD002997.pub3
    1. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG (2008) Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 177: 148–155 10.1164/rccm.200707-1134OC
    1. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, et al. (2013) Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. doi:10.1136/thoraxjnl-2012-202698

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться